Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management

[1]  C. Karner,et al.  Combination inhaled steroid and long-acting beta₂-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. , 2016, The Cochrane database of systematic reviews.

[2]  D. Postma,et al.  Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. , 2015, American journal of respiratory and critical care medicine.

[3]  R. Zuwallack,et al.  An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. , 2015, American journal of respiratory and critical care medicine.

[4]  Courtney Crim,et al.  Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. , 2015, Annals of the American Thoracic Society.

[5]  F. Martinez,et al.  Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial , 2015, The Lancet.

[6]  J. Wedzicha,et al.  Corrigendum to “Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations” [Respir Med 108 (2014) 1153–1162] , 2015 .

[7]  A. Sharafkhaneh,et al.  The Asthma COPD Overlap Syndrome (ACOS) , 2015, Current Allergy and Asthma Reports.

[8]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[9]  C. Auffray,et al.  Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014. , 2015, American journal of respiratory and critical care medicine.

[10]  F. Martinez,et al.  Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. , 2015, Annals of the American Thoracic Society.

[11]  B. Celli,et al.  Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. , 2015, American journal of respiratory and critical care medicine.

[12]  I. Pavord,et al.  Association Between Pathogens Detected Using Quantitative Polymerase Chain Reaction With Airway Inflammation in COPD at Stable State and Exacerbations , 2014, Chest.

[13]  S. Johnston,et al.  Inhaled glucocorticoids and COPD exacerbations. , 2015, The New England journal of medicine.

[14]  James A. Nathan,et al.  Muscle wasting in disease: molecular mechanisms and promising therapies , 2014, Nature Reviews Drug Discovery.

[15]  K. Bracke,et al.  Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease. , 2014, Annals of the American Thoracic Society.

[16]  E. Bleecker,et al.  Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. , 2014, The Lancet. Respiratory medicine.

[17]  A. Agustí,et al.  Inhaled steroids in COPD: when should they be used? , 2014, The Lancet. Respiratory medicine.

[18]  Jordi Giner,et al.  Identification of airway bacterial colonization by an electronic nose in Chronic Obstructive Pulmonary Disease. , 2014, Respiratory medicine.

[19]  Craig E Wheelock,et al.  Network analysis in the investigation of chronic respiratory diseases. From basics to application. , 2014, American journal of respiratory and critical care medicine.

[20]  A. Papi,et al.  INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD , 2014, European Respiratory Journal.

[21]  Dave Singh,et al.  Eosinophilic inflammation in COPD: prevalence and clinical characteristics , 2014, European Respiratory Journal.

[22]  M. Decramer,et al.  Withdrawal of inhaled glucocorticoids and exacerbations of COPD. , 2014, The New England journal of medicine.

[23]  Weon S Chung,et al.  Inhaled corticosteroids and the increased risk of pulmonary tuberculosis: a population‐based case–control study , 2014, International journal of clinical practice.

[24]  J. Roca,et al.  Network medicine analysis of COPD multimorbidities , 2014, Respiratory Research.

[25]  T. To,et al.  Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. , 2014, JAMA.

[26]  J. Wedzicha,et al.  Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease , 2014, Respiratory Research.

[27]  P. Jones,et al.  Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. , 2014, Respiratory medicine.

[28]  A. Agustí,et al.  Network medicine, multimorbidity and the lung in the elderly , 2014, European Respiratory Journal.

[29]  Meilan K. Han,et al.  Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. , 2014, American journal of respiratory and critical care medicine.

[30]  I. Pavord,et al.  Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis , 2014, European Respiratory Journal.

[31]  Martine Vrijheid,et al.  The exposome: a new paradigm to study the impact of environment on health , 2014, Thorax.

[32]  Courtney Crim,et al.  Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. , 2014, American journal of respiratory and critical care medicine.

[33]  A. Agustí.  The path to personalised medicine in COPD , 2014, Thorax.

[34]  I. Adcock,et al.  Cytokine inhibition in the treatment of COPD , 2014, International journal of chronic obstructive pulmonary disease.

[35]  Kayleigh Kew,et al.  Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. , 2014, Cochrane Database of Systematic Reviews.

[36]  Albert-László Barabási,et al.  A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease , 2014, BMC Systems Biology.

[37]  J. Frampton.  QVA149 (Indacaterol/Glycopyrronium Fixed-Dose Combination): A Review of Its Use in Patients with Chronic Obstructive Pulmonary Disease , 2014, Drugs.

[38]  K. Coombes,et al.  Transcriptomic architecture of the adjacent airway field cancerization in non-small cell lung cancer. , 2014, Journal of the National Cancer Institute.

[39]  Stephanie A. Santorico,et al.  Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema , 2014, Thorax.

[40]  Nicolas Roche,et al.  Identification of Clinical Phenotypes Using Cluster Analyses in COPD Patients with Multiple Comorbidities , 2014, BioMed research international.

[41]  R. Stockley,et al.  α-1-Antitrypsin deficiency: clinical variability, assessment, and treatment. , 2014, Trends in molecular medicine.

[42]  D. Postma,et al.  Integrating real-life studies in the global therapeutic research framework. , 2013, The Lancet. Respiratory medicine.

[43]  Meilan K. Han,et al.  Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial , 2013, European Respiratory Journal.

[44]  G. Pledger,et al.  Tiotropium Respimat inhaler and the risk of death in COPD. , 2013, The New England journal of medicine.

[45]  P. Poole,et al.  Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. , 2013, The Cochrane database of systematic reviews.

[46]  Charles A Powell,et al.  An official American Thoracic Society/European Respiratory Society statement: the role of the pulmonologist in the diagnosis and management of lung cancer. , 2013, American journal of respiratory and critical care medicine.

[47]  D. Postma,et al.  Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity , 2013, Thorax.

[48]  T. To,et al.  Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. , 2013, JAMA internal medicine.

[49]  I. Pavord,et al.  Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? , 2013, Thorax.

[50]  C. Cates,et al.  Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. , 2013, The Cochrane database of systematic reviews.

[51]  J. Zak,et al.  Chronic Obstructive Pulmonary Disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. , 2013, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[52]  F. Martinez,et al.  Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. , 2013, The Lancet. Respiratory medicine.

[53]  K. Verhamme,et al.  Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD , 2013, European Respiratory Journal.

[54]  E. Bateman,et al.  Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. , 2013, The Lancet. Respiratory medicine.

[55]  J. Soriano,et al.  A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC) , 2013, Primary care respiratory journal : journal of the General Practice Airways Group.

[56]  Charles Auffray,et al.  Application of ’omics technologies to biomarker discovery in inflammatory lung diseases , 2013, European Respiratory Journal.

[57]  D. Price,et al.  Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. , 2012, Primary care respiratory journal : journal of the General Practice Airways Group.

[58]  P. S. Wong,et al.  Evaluation of changes in guidelines for medication management of stable chronic obstructive pulmonary disease. , 2012, Journal of evaluation in clinical practice.

[59]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[60]  Alvar Agusti,et al.  The COPD control panel: towards personalised medicine in COPD , 2012, Thorax.

[61]  T. Lasserson,et al.  Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.

[62]  Rudi Balling,et al.  Revolutionizing medicine in the 21st century through systems approaches. , 2012, Biotechnology journal.

[63]  K. Fong,et al.  Inhaled corticosteroids for stable chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.

[64]  Christopher E Brightling,et al.  Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. , 2012, American journal of respiratory and critical care medicine.

[65]  Courtney Crim,et al.  Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype , 2012, PloS one.

[66]  Ara Darzi,et al.  Preparing for precision medicine. , 2012, The New England journal of medicine.

[67]  F. Rutten,et al.  Balance measures for propensity score methods: a clinical example on beta‐agonist use and the risk of myocardial infarction , 2011, Pharmacoepidemiology and Drug Safety.

[68]  J. Hogg,et al.  Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. , 2011, The New England journal of medicine.

[69]  M. Cosio,et al.  Lung cancer in patients with chronic obstructive pulmonary disease-- incidence and predicting factors. , 2011, American journal of respiratory and critical care medicine.

[70]  F. Martinez,et al.  The National Emphysema Treatment Trial (NETT) Part II: Lessons learned about lung volume reduction surgery. , 2011, American journal of respiratory and critical care medicine.

[71]  Christopher E Brightling,et al.  Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. , 2011, American journal of respiratory and critical care medicine.

[72]  John Connett,et al.  Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[73]  Stephanie J. C. Taylor,et al.  Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodology , 2011, Respiratory research.

[74]  Adnan Custovic,et al.  Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. , 2011, The Journal of allergy and clinical immunology.

[75]  C. Brightling,et al.  Procalcitonin and C-Reactive Protein in Hospitalized Adult Patients With Community-Acquired Pneumonia or Exacerbation of Asthma or COPD , 2010, Chest.

[76]  K. Rabe.  Roflumilast for the treatment of chronic obstructive pulmonary disease , 2010, Expert review of respiratory medicine.

[77]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[78]  Edwin K Silverman,et al.  Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.

[79]  Edwin K Silverman,et al.  Chronic obstructive pulmonary disease phenotypes: the future of COPD. , 2010, American journal of respiratory and critical care medicine.

[80]  D. Noble,et al.  Systems Biology: An Approach , 2010, Clinical pharmacology and therapeutics.

[81]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[82]  I. Adcock,et al.  Glucocorticoid resistance in inflammatory diseases , 2009, The Lancet.

[83]  S. Antoniu.  UPLIFT Study: the effects of long-term therapy with inhaled tiotropium in chronic obstructive pulmonary disease , 2009, Expert opinion on pharmacotherapy.

[84]  D. Tashkin,et al.  Formoterol and Tiotropium Compared With Tiotropium Alone for Treatment of COPD , 2009, COPD.

[85]  I. Adcock,et al.  Glucocorticoid resistance in infl ammatory diseases , 2009 .

[86]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[87]  T. Seemungal,et al.  The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.

[88]  A. Barabasi,et al.  Network medicine--from obesity to the "diseasome". , 2007, The New England journal of medicine.

[89]  A. Barabasi,et al.  Human disease classification in the postgenomic era: A complex systems approach to human pathobiology , 2007, Molecular systems biology.

[90]  I. Pavord,et al.  Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial , 2007, European Respiratory Journal.

[91]  J. Bourbeau,et al.  Tiotropium in Combination with Placebo, Salmeterol, or FluticasoneSalmeterol for Treatment of Chronic Obstructive Pulmonary Disease , 2007, Annals of Internal Medicine.

[92]  J. Struck,et al.  Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. , 2007, Chest.

[93]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[94]  J. Curtis,et al.  Procalcitonin-guided antibiotic therapy in COPD exacerbations: closer but not quite there. , 2007, Chest.

[95]  N. Anthonisen,et al.  Mortality in COPD: role of comorbidities , 2006, European Respiratory Journal.

[96]  S. Sethi,et al.  Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.

[97]  F. Maltais,et al.  Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment , 2006, European Respiratory Journal.

[98]  D. Postma,et al.  Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial , 2005, Thorax.

[99]  I. Pavord,et al.  Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease , 2005, Thorax.

[100]  R. Sansores,et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[101]  J. van der Palen,et al.  Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. , 2002, American journal of respiratory and critical care medicine.

[102]  T. Seemungal,et al.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.

[103]  N. Anthonisen,et al.  Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. , 2001, American journal of respiratory and critical care medicine.

[104]  Christine Jenkins,et al.  GOLD SCIENTIFIC COMMITTEE. GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. NHLBI/WHO GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (COLD) WORKSHOP SUMMARY , 2001 .

[105]  I. Pavord,et al.  Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial , 2000, The Lancet.

[106]  R. Stockley,et al.  Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. , 2000, The American journal of medicine.

[107]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[108]  B Rosner,et al.  Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. , 1998, American journal of respiratory and critical care medicine.

[109]  J. Bousquet,et al.  Corticosteroid reversibility in COPD is related to features of asthma. , 1997, American journal of respiratory and critical care medicine.